All In Biotech

Drug Trial Radar · NCT03197818

Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)

A 24-week, Double Blind, Double Dummy, Randomized, Multinational, Multicentre, 2-arm Parallel Group,Active Controlled Clinical Trial of Fixed Combination of Beclometasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide Administered Via pMDI (CHF 5993) Versus the Fixed Combination of Budesonide Plus Formoterol Fumarate (Symbicort® Turbuhaler®) in Patients With Chronic Obstructive Pulmonary Disease

Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 708 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

708

Actual

Start

Dec 14, 2016

Primary completion

May 26, 2020

Study completion May 26, 2020

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Jun 23, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective • To demonstrate the superiority of CHF 5993 pressurised metered dose inhaler (pMDI) over Symbicort® Turbuhaler® in terms of pulmonary function (change from baseline in pre-dose morning forced expiratory volume in the first second of a forced vital capacity manoeuvre \[FEV1\] and 2-hour post-dose morning FEV1 at Week 24). Secondary Objectives Key secondary objective: • To demonstrate the superiority of CHF 5993 pMDI over Symbicort® Turbuhaler® in terms of pulmonary function (change from baseline in pre-dose morning FEV1 and 2-hour post-dose morning FEV1 at Week 24) in the subgroup of Chinese population. Other secondary objectives: * To evaluate the effect of CHF 5993 pMDI on other lung function parameters, patient's health status and clinical outcome measures; * To collect data in order to assess the impact of study treatments on health economic outcomes; * To assess the safety and the tolerability of the study treatments.

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)

Interventions

  • CHF 5993 100/6/12.5 µgDrug

    Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose

  • 160 µg budesonide + 4.5 µg formoterol fumarateDrug

    Fixed combination of budesonide 160 µg plus formoterol fumarate 4.5 µg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Pre-dose Forced Expiratory Volume Within the First Second (FEV1) at Week 24Time frame: Week 24 (Visit 6)
  2. Change From Baseline in 2-hour Post-dose FEV1 at Week 24Time frame: Week 24 (Visit 6)

Locations

64 sites in 3 countries. Site status is shown where the registry gives one.

  • Chiesi Clinical Trial Site 156001

    Guangzhou, China

  • Chiesi clinical Trial Site 156031

    Beijing, Beijing Municipality, China

  • Chiesi Clinical Trial Site 156026

    Beijing, Beijing Municipality, China

  • Chiesi clinical Trial Site 156017

    Beijing, Beijing Municipality, China

  • Chiesi Clinical Trial Site 156012

    Beijing, Beijing Municipality, China

  • Chiesi Clinical Trial Site 156045

    Chongqing, Chongqing Municipality, China

  • Chiesi Clinical Trial Site 156002

    Fuzhou, Fujian, China

  • Chiesi clinical Trial Site 156024

    Foshan, Guangdong, China

  • Chiesi Clinical Trial Site 156048

    Guangzhou, Guangdong, China

  • Chiesi Clinical Trial Site 156013

    Guangzhou, Guangdong, China

  • Chiesi Clinical Trial Site 156008

    Zhanjiang, Guangdong, China

  • Chiesi Clinical Trial site 156003

    Nanning, Guangxi, China

  • Chiesi clinical Trial Site 156020

    Haikou, Hainan, China

  • Chiesi Clinical Trial Site 156044

    Shijiangzhuang, Hebei, China

  • Chiesi Clinical Trial Site 156040

    Changsha, Hunan, China

  • Chiesi Clinical Trial Site 156043

    Baotou, Inner Mongolia, China

  • Chiesi Clinical Trial Site 156015

    Baotou, Inner Mongolia, China

  • Chiesi Clinical Trial Site 156004

    Huai'an, Jiangsu, China

  • Chiesi clinical Trial Site 156033

    Jiangyin, Jiangsu, China

  • Chiesi clinical Trial Site 156022

    Nanjing, Jiangsu, China

  • Chiesi Clinical Trial Site 156047

    Jiujiang, Jiangxi, China

  • Chiesi Clinical Trial Site 156041

    Nanchang, Jiangxi, China

  • Chiesi clinical Trial Site 156028

    Nanchang, Jiangxi, China

  • Chiesi Clinical Trial Site 156042

    Pingxiang, Jiangxi, China

  • Chiesi clinical Trial Site 156023

    Changchun, Jilin, China

  • Chiesi Clinical Trial Site 156036

    Changchun, Jilin, China

  • Chiesi clinical Trial Site 156019

    Changchun, Jilin, China

  • Chiesi Clinical Trial Site 156007

    Shenyang, Liaoning, China

  • Chiesi clinical Trial Site 156025

    Yinchuan, Ningxia, China

  • Chiesi Clinical Trial Site 156014

    Shanghai, Shanghai Municipality, China

  • Chiesi clinical Trial Site 156037

    Shanghai, Shanghai Municipality, China

  • Chiesi Clinical Trial Site 156005

    Shanghai, Shanghai Municipality, China

  • Chiesi Clinical Trial Site 156006

    Shanghai, Shanghai Municipality, China

  • Chiesi Clinical Trial Site 156011

    Shanghai, Shanghai Municipality, China

  • Chiesi Clinical Trial Site 156038

    Shanghai, Shanghai Municipality, China

  • Chiesi Clinical Trial Site 156039

    Taiyuan, Shanxi, China

  • Chiesi clinical Trial Site 156035

    Chengdu, Sichuan, China

  • Chiesi Clinical Trial Site 156010

    Chengdu, Sichuan, China

  • Chiesi clinical Trial Site 156032

    Chongqing, Sichuan, China

  • Chiesi clinical Trial Site 156034

    Tianjin, Tianjin Municipality, China

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.